This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

News
Lucy Chard
20 Feb 2024

Genome study discovers 275 million new variants across a diverse population

A new genome study undertaken in the US, accounting for a diverse range of people, has led to the discovery of nearly 300 million new genetic variants, which could inform markers of disease. 

Research into genetic codes over the past few decades has changed the face of drug development, opening up a whole new world of prospects and more efficient ways to help people in need. 

The Human Genome Project, which ran from 1990 to 2003, identified, sequenced, and mapped the entire human genome. Since then, scientists have been working to sequence data from people for a variety of reasons, one of which is to help understand rare genetic diseases, and to develop new drugs that can be more targeted to the patient’s needs. 

Recently, one study in the US analysed the genetic code of around 250,000 volunteers. The study found over 275 million new genetic variants, showing the extent of the variation in the human population, and hopefully giving some answers as to why disease burden can differ so much across different genetic groups. 

Historically, whole genome sequencing has been conducted on small range of people, with quite a distinct lack of diversity – almost 90% of studies have been undertaken on people of European decent – this new sequencing project rectifies this otherwise blinkered view, by specifically ensuring that previously underrepresented groups were included in the study. The US National Institutes of Health funded a study, – "All of Us" – and unearthed a total of 1 billion genetic variants, which this study adds to.

"Sequencing diverse populations can lead to new drug targets that are relevant to everyone," commented Josh Denny, a study author and its chief executive. "It can also help uncover disparities that lead to specific treatments for people that are experiencing higher burdens of disease or different disease."

The study has brought up some interesting insights; we know that genetic variation doesn’t have a direct impact on people's health, however, the study showed that some genetic variations occurred in geographical areas that have a connection to disease risk, nearly 4 million of the newly discovered codes in fact. 

"This is huge," stated Denny. 

To further this line of investigation, the study group hopes to collect health information, including DNA data, on 1 million people, with the aim of gaining an even greater understanding of the genetic effects on health and disease. By conducting this research on a more diverse population, researchers are hoping to understand how different drug and medicines interact and can be used in these populations, as opposed to the populations that most drug research is currently based on. 

"It's a huge gap, obviously, because most of the world's population is not of European ancestry," Denny pointed out.

We have already seen the impact that genetic variation has on drug discovery, taking PCSK9 inhibitors as an example, a class of drugs that lower the levels of low-density lipoprotein (LDL), which were discovered when the genetic code of 5,000 people in Dallas of African ancestry was sequenced. 

By opening up the cohort of subjects for genetic sequencing, we are opening up a vast world of opportunity for future drug discovery and development, and can be used in the future to ascertain a population’s or person’s risk of disease. 

Learn more about the All Of Us study below. 

Related News

  • News A Day in the Life of Oncology Start-Up Co-Founder & CEO

    This Women's month we are highlighting stories of women in the pharma industry (building on what we do every month to support women), so for the Day in the Life of we are speaking to Sharon Cunningham who is the Co-founder and CEO of Shorla On...
  • News Women in Pharma: Manufacturing personal and team success

    Our monthly Women in Pharma series highlights the influential lives and works of impactful women working across the pharmaceutical industry, and how the industry can work towards making the healthcare industry and workplace more equitable and inclusive...
  • News Women in Pharma: Connecting accessible pharma packaging to patients – a Pharmapack Special

    Throughout our Women in Pharma series, we aim to highlight how CPHI events encourage discussions around diversity, equity, and inclusion initiatives in the pharmaceutical industry. 
  • News Women in Pharma: Delivering on global access to medicines

    Our monthly Women in Pharma series highlights the influential lives and works of impactful women working across the pharmaceutical industry, and how the industry can work towards making the healthcare industry and workplace more equitable and inclusive...
  • News Women in Pharma: Our hopes for 2025 and beyond

    Our last instalment for 2024 of the Women in Pharma series brings you messages direct from the Informa Markets CPHI team as they discuss the advice and insights they have carried throughout their roles working at CPHI, and what they hope to see for the...
  • News Closing 2024 with Editors' picks of top articles from the past year

    Coming to the end of 2024 and it’s certainly been a busy year, for CPHI and for the rest of the pharmaceutical and healthcare industry. Topics of conversation throughout the last 12 months have been varied, touching on the technical, to the polit...
  • News Day in the Life of a Green Chief Financial Officer

    Our latest look into the daily lives of the people behind the pharma community brings us to meet Juan Jose Piedra Galan, Global Financial Planning & Analysis Manager for Galderma, otherwise known as 'The Green CFO'.  
  • News Women in Pharma: Reflections from Behind the Scenes

    In this instalment of our monthly series, the team that brings you the Women in Pharma series each month sits down for a heart-to-heart on what the series means to them, and how they hope to continue their work in the future. 

Recently Visited